Skip to main content
Clinical Trials/NCT00145262
NCT00145262
Unknown
Not Applicable

Therapeutic Angiogenesis Using Cell Transplantation (TACT) Study at Nagoya

Nagoya University1 site in 1 countryAugust 2003

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Buerger Disease
Sponsor
Nagoya University
Locations
1
Last Updated
20 years ago

Overview

Brief Summary

Clinical studies have established that implantation of bone marrow mononuclear cells (BM-MNCs) or peripheral blood mononuclear cells (PB-MNCs) into ischaemic limbs increases collateral vessel formation. We, the investigators at Nagoya University, further investigated the efficacy and safety of autologous implantation of BM-MNCs or PB-MNCs in patients with severe ischaemic limbs who have no other alternative therapeutic options. We also examined a potential limiting factor which reduced the efficacy of therapeutic angiogenesis using cell transplantation (TACT).

Registry
clinicaltrials.gov
Start Date
August 2003
End Date
TBD
Last Updated
20 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Subjects who have chronic limb ischemia, including rest pain, non-healing ischemic ulcers, or both, and who are not candidates for nonsurgical or surgical revascularisation.

Exclusion Criteria

  • Poorly controlled diabetes mellitus (hemoglobin A1c \[HbA1c\] \> 6.5% and proliferative retinopathy)
  • Evidence of malignant disorder during the past 5 years
  • Subjects who cannot survive more than 1 year with other complications
  • Malignant rheumatic arthritis

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials